The immuno-oncology collaboration intends to advance development of novel immune checkpoint therapies. Baxalta agreed to make an upfront payment of $175m to Symphogen in exchange for exclusive rights
The companies have signed a collaboration agreement under which Pfizer and Merck will combine their avelumab cancer drug with Syndax’s entinostat, a treatment currently being studied in patients
The compound will be used to develop new treatments for hepatocellular carcinoma (HCC), the most common type of liver cancer in Asia. LB-100 is currently not approved to
This new strategic collaboration is expected to leverage the expertise of Araim Pharmaceuticals in scientific discovery and research with Vault Bioventures’ proven capability in clinical and regulatory development
Under the terms of the agreement with Acerus, Endo will continue to sell and distribute Natesto in the US until the effective date of termination. Acerus president and
Preeclampsia is one of the most common medical complications of pregnancy, and a leading cause of premature births, stillbirths and early neonatal and maternal deaths. Severe preeclampsia occurs
GBT440 is an oral, once-daily SCD therapy that works by increasing hemoglobin’s affinity for oxygen. The company is investigating the drug candidate in both healthy subjects and SCD
The randomized, double-blind, placebo-controlled, registration-quality Phase 2 clinical trial AtEase is being conducted at about 25 US sites. The study has been designed to assess the safety of
The phase 1/2 open-label, multi-center, clinical trial is for patients with CD30-expressing relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas (NHL), including diffuse large B-cell lymphoma (DLBCL), peripheral
L-DOS47 is the company’s first immunoconjugate based drug candidate in development based on its DOS47 platform technology designed to use a new approach to amend the microenvironmental conditions
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.